Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Sees Significant Growth in Short Interest

Carl Zeiss Meditec AG (OTCMKTS:CZMWY – Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 180 shares, a growth of 386.5% from the July 15th total of 37 shares. Based on an average daily trading volume, of 2,823 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

CZMWY has been the topic of several analyst reports. UBS Group downgraded Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research note on Tuesday. Zacks Research cut Carl Zeiss Meditec from a “hold” rating to a “strong sell” rating in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

Get Carl Zeiss Meditec alerts:

View Our Latest Stock Report on Carl Zeiss Meditec

Carl Zeiss Meditec Price Performance

CZMWY traded up $2.07 during trading on Friday, reaching $37.11. The company’s stock had a trading volume of 5,305 shares, compared to its average volume of 4,445. The company’s fifty day moving average price is $32.24 and its 200-day moving average price is $31.09. Carl Zeiss Meditec has a 52-week low of $26.65 and a 52-week high of $55.94.

Carl Zeiss Meditec Company Profile

(Get Free Report)

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.

Featured Stories

• Five stocks we like better than Carl Zeiss Meditec
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?
• CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
• Joint Operations: Curaleaf Makes a Play for Aurora Cannabis

Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.